Anti-angiogenic properties of calcium trifluoroacetate

被引:2
|
作者
Bussolati, Benedetta [2 ]
Ribatti, Domenico [3 ]
Munaron, Luca [4 ]
Bartorelli, Alberto [5 ]
Bussolati, Gianni [1 ]
机构
[1] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy
[2] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, I-10126 Turin, Italy
[3] Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy
[4] Univ Turin, Ctr Complex Syst Mol Biol & Med SyBioM, Nanostruct Interfaces & Surfaces Ctr Excellence N, Dept Anim & Human Biol, I-10126 Turin, Italy
[5] Univ Milan, I-20122 Milan, Italy
关键词
Angiogenesis; Calcium; Trifluoroacetate; NITRIC-OXIDE PRODUCTION; CHORIOALLANTOIC MEMBRANE; INTRACELLULAR CALCIUM; MECHANISMS; VEGF; PROLIFERATION;
D O I
10.1016/j.mvr.2009.07.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Endothelial cell proliferation and the formation of new vessels are strictly regulated by angiogenic factors (e.g., VEGF) that induce the activation of signal transduction pathways controlled by calcium dynamics. Using in vitro and in vivo experiments, we investigated the effect of calcium trifluoroacetate (CaTFAc), a complex, poorly dissociated salt that is characterized by its low toxicity, on angiogenesis. In vitro, CaTFAc inhibited VEGF-induced effects on endothelial cell proliferation. In two in vivo models of angiogenesis, a Matrigel plug in mice and a chick embryo chorioallantoic membrane, CaTFAc inhibited the VEGF-induced formation of new vessels. The exact mechanism of action is still under investigation, but in vitro experiments demonstrate that CaTFAc induced a reversible increase in the levels of intracellular calcium under basal conditions and prevented calcium signaling induced by VEGF. These results are the first to suggest that CaTFAc may be useful for the treatment of diseases caused by enhanced angiogenesis. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 50 条
  • [41] Preeclampsia and the anti-angiogenic state
    Agarwal, Isha
    Karumanchi, S. Ananth
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2011, 1 (01) : 17 - 21
  • [42] Anti-angiogenic gene therapy
    Fife, K
    Buluwela, L
    Miller, A
    Coombes, RC
    Bower, M
    BRITISH JOURNAL OF CANCER, 1998, 78 : 18 - 18
  • [43] Synthesis of anti-angiogenic isocoumarins
    Yuan, HQ
    Junker, B
    Helquist, P
    Taylor, RE
    CURRENT ORGANIC SYNTHESIS, 2004, 1 (01) : 1 - 9
  • [44] Anti-angiogenic therapy in glioma
    Nicholas Butowski
    Clinical and Translational Oncology, 2011, 13 : 294 - 300
  • [45] BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY
    Das, Millie
    Wakelee, Heather
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S442 - S443
  • [46] ANTI-ANGIOGENIC ACTIVITY OF SURAMIN
    COLLINS, D
    GAGLIARDI, A
    FASEB JOURNAL, 1992, 6 (05): : A1600 - A1600
  • [47] Anti-angiogenic effect of α-mangostin
    Tomoko Shiozaki
    Miyuki Fukai
    Elvira Hermawati
    Lia Dewi Juliawaty
    Yana Maolana Syah
    Euis Holisotan Hakim
    Ploenthip Puthongking
    Toshihiro Suzuki
    Kaoru Kinoshita
    Kunio Takahashi
    Kiyotaka Koyama
    Journal of Natural Medicines, 2013, 67 : 202 - 206
  • [48] Anti-angiogenic therapy in glioma
    Butowski, Nicholas
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (05): : 294 - 300
  • [49] Anti-angiogenic therapy in rhabdomyosarcoma
    Casanova, M.
    PEDIATRIC REPORTS, 2012, 4 : 35 - 39
  • [50] Paradox of anti-angiogenic drugs
    不详
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1326 - 1326